Educational Series – Update on Long-Acting Reversible Contraceptives

Long-acting reversible contraceptives are one of the most effective forms of contraception for women, comparable to permanent contraception. There is no difference in the efficacy between typical use and perfect use, as these methods do not require any user action beyond insertion. In 2019, Mirena® (levonorgestrel 52mg), Jaydess® (levonorgestrel 13.5mg) and Jadelle® (levonorgestrel 2x75mg) became funded in New Zealand, significantly improving access for patients and clinicians. While the levonorgestrel subdermal implant Jadelle® is already available on a practitioner supply order in New Zealand, PHARMAC has increased access to long-acting reversible contraceptives, with the intrauterine devices Mirena® and Jaydess® available on practitioner supply order from August 2025. Moreover, the registered duration of use for Mirena® for contraception has been extended to 8 years, making it an even more convenient option. This review covers the recent literature outlining the benefits and potential management considerations for the use of long-acting reversible contraceptives in New Zealand women.